AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12594152 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1%
Number of subjects: 108
Study 12594152 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2%
Number of subjects: 108
Study 10802796 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr)
Number of subjects: 36
Study 10802796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8635377 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg every 10 min)
Number of subjects: 8
Study 8635377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 microg every 10 min)
Number of subjects: 8
Study 8635377 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (ED50F)
Number of subjects: 8
Study 8635377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (ED50F)
Number of subjects: 8
Study 8635377 — intervention group
Group type: COMPARATOR
Intervention: Albuterol and Fenoterol (Heart Rate)
Number of subjects: 8
Study 1484773 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-message group heard a tape containing the backward messages recorded three times in succession
Number of subjects: 82
Study 1484773 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-message group heard a tape with the same backward messages recorded six times in succession
Number of subjects: 82
Study 1484773 — intervention group
Group type: COMPARATOR
Intervention: Control group heard nonbackward recorded music
Number of subjects: 82
Study 3883162 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 12
Study 3883162 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 12
Study 30791125 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 40 μg/day
Number of subjects: 216
Study 30791125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (ATZ) 300 μg/day
Number of subjects: 216
Study 29036427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined enalapril 10 mg and folic acid 0.8 mg tablet
Number of subjects: 3230
Study 29036427 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg tablet alone
Number of subjects: 3230
Study 29036427 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐averaged diastolic blood pressure (DBP) of ≤80 mmHg
Number of subjects: 3230
Study 29036427 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐averaged SBP of ≤130 mmHg
Number of subjects: 3230
Study 29036427 — intervention group
Group type: COMPARATOR
Intervention: Time‐averaged SBP of 135 to ≤140 mmHg
Number of subjects: 3230
Study 26871238 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg 0.5% hyperbaric bupivacaine + 0.1 mg morphine)
Number of subjects: 90
Study 26871238 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 mg 0.5% hyperbaric bupivacaine + 25 µg fentanyl)
Number of subjects: 90
Study 26871238 — intervention group
Group type: COMPARATOR
Intervention: Control (5 mg 0.5% hyperbaric bupivacaine + physiologic saline)
Number of subjects: 90
Study 23095095 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 0
Study 23095095 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care therapies
Number of subjects: 0
Study 23249443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist-led strategy
Number of subjects: 5
Study 23249443 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led strategy
Number of subjects: 5
Study 23249443 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led strategy
Number of subjects: 5
Study 23249443 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning strategy
Number of subjects: 5
Study 23249443 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5
Study 21060072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180-mg loading dose followed by 90 mg twice daily
Number of subjects: 7544
Study 21060072 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300-mg loading dose followed by 75 mg daily
Number of subjects: 7544
Study 21060072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 7544
Study 21060072 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7544
Study 17425224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 5 mg
Number of subjects: 26
Study 17425224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 26
Study 17425224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 14673397 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine + fentanyl
Number of subjects: 28
Study 14673397 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine + fentanyl
Number of subjects: 28
Study 11087881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg daily
Number of subjects: 8076
Study 11087881 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 8076
Study 8615705 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with lovastatin
Number of subjects: 612
Study 8615705 — intervention group
Group type: COMPARATOR
Intervention: Stepped-care regimen
Number of subjects: 612
Study 8615705 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs of care
Number of subjects: 612
Study 1307655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacids (Alugastrin and Alumag)
Number of subjects: 0
Study 1307655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 1307655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1307655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacids and ranitidine
Number of subjects: 0
Study 6236738 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg daily
Number of subjects: 28
Study 6236738 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg t.i.d.
Number of subjects: 28
Study 30985644 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 204
Study 30985644 — intervention group
Group type: COMPARATOR
Intervention: Trichlormethiazide 1 mg
Number of subjects: 204
Study 28045374 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling (P)
Number of subjects: 102
Study 28045374 — intervention group
Group type: COMPARATOR
Intervention: Non-ILM peeling (NP)
Number of subjects: 102
Study 25887103 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic biliary drainage
Number of subjects: 106
Study 25887103 — intervention group
Group type: COMPARATOR
Intervention: Preoperative percutaneous transhepatic biliary drainage
Number of subjects: 106
Study 25887103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 106
Study 23664718 — intervention group
Group type: EXPERIMENTAL
Intervention: OU care with stress CMR
Number of subjects: 105
Study 23664718 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 21613242 — intervention group
Group type: EXPERIMENTAL
Intervention: $100 incentive
Number of subjects: 3550
Study 21613242 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 incentive
Number of subjects: 3550
Study 21613242 — intervention group
Group type: EXPERIMENTAL
Intervention: $2 preincentive
Number of subjects: 3550
Study 21613242 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal prenotification letter
Number of subjects: 3550
Study 21613242 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 3550
Study 21613242 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry into a $200 lottery
Number of subjects: 3550
Study 20122589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson A system at 10 L/min
Number of subjects: 10
Study 20122589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson D system at 10 L/min
Number of subjects: 10
Study 20122589 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle anesthesia system at 10 L/min
Number of subjects: 10
Study 20122589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson A system at 5 L/min
Number of subjects: 10
Study 20122589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson D system at 5 L/min
Number of subjects: 10
Study 20122589 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle anesthesia system at 5 L/min
Number of subjects: 10
Study 17316865 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) spray
Number of subjects: 46
Study 17316865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17316865 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) spray after crossover
Number of subjects: 46
Study 14665886 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 300
Study 14665886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/Bupivacaine
Number of subjects: 300
Study 10852142 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted preventive strategies addressing six identified risk factors
Number of subjects: 852
Study 10852142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 852
Study 8986845 — intervention group
Group type: EXPERIMENTAL
Intervention: Asperger syndrome (AS) patients rated for pedantic speech
Number of subjects: 17
Study 8986845 — intervention group
Group type: COMPARATOR
Intervention: High-functioning autism (HFA) patients rated for pedantic speech
Number of subjects: 17
Study 1479161 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 60
Study 1479161 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 60
Study 1479161 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily (doubled dose after 4 weeks)
Number of subjects: 60
Study 1479161 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg twice daily (doubled dose after 4 weeks)
Number of subjects: 60
Study 1479161 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily (for refractory patients)
Number of subjects: 60
Study 6464812 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertion training treatment
Number of subjects: 0
Study 6464812 — intervention group
Group type: COMPARATOR
Intervention: Placebo-counseling program
Number of subjects: 0
Study 30612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 100 mg once daily for 10 days
Number of subjects: 24
Study 30612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 400 mg once daily for 10 days
Number of subjects: 24
Study 30612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 800 mg once daily for 10 days
Number of subjects: 24
Study 30612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 1200 mg once daily for 10 days
Number of subjects: 24
Study 30612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 2400 mg once daily for 10 days
Number of subjects: 24
Study 30612858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30167856 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 91
Study 30167856 — intervention group
Group type: COMPARATOR
Intervention: Double balloon catheter
Number of subjects: 91
Study 30167856 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter (intrauterine fetal death)
Number of subjects: 91
Study 30167856 — intervention group
Group type: COMPARATOR
Intervention: Double balloon catheter (live fetuses)
Number of subjects: 91
Study 30167856 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter (history of vaginal delivery)
Number of subjects: 91
Study 30167856 — intervention group
Group type: COMPARATOR
Intervention: Double balloon catheter (no history of vaginal delivery)
Number of subjects: 91
Study 26821137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemi- or total hip arthroplasty
Number of subjects: 141
Study 24220616 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² once daily for 5 days every 4 weeks (n = 242)
Number of subjects: 485
Study 24220616 — intervention group
Group type: COMPARATOR
Intervention: Treatment choice (supportive care or cytarabine 20 mg/m² once daily for 10 days every 4 weeks; n = 243)
Number of subjects: 485
Study 22936892 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV+FTC-TDF
Number of subjects: 1571
Study 22936892 — intervention group
Group type: COMPARATOR
Intervention: EFV+3TC-ZDV
Number of subjects: 1571
Study 22936892 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV+DDI+FTC
Number of subjects: 1571
Study 21182602 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine
Number of subjects: 100
Study 18684288 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation (RMN)
Number of subjects: 32
Study 18684288 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) manual approach
Number of subjects: 32
Study 16183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 3.3 g/100 kcal
Number of subjects: 77
Study 16183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 3.0 g/100 kcal
Number of subjects: 77
Study 16183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 2.7 g/100 kcal
Number of subjects: 77
Study 16183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake greater than 2.7 g/100 kcal
Number of subjects: 77
Study 12562576 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine + Reboxetine (4 mg/day)
Number of subjects: 26
Study 12562576 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine + Placebo
Number of subjects: 26
Study 10379448 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlanger silver catheter
Number of subjects: 0
Study 10379448 — intervention group
Group type: COMPARATOR
Intervention: Statistical model analyzing first catheter only (independent data)
Number of subjects: 0
Study 10379448 — intervention group
Group type: COMPARATOR
Intervention: Statistical model analyzing several catheters from the same patient (dependent data)
Number of subjects: 0
Study 8678065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate Dialysis (BD)
Number of subjects: 12
Study 8678065 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 12
Study 8678065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-Free Biofiltration (AFB)
Number of subjects: 12
Study 1904908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 91
Study 1904908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 31809349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosecond Pulsed Electric Field Treatment (NPS)
Number of subjects: 58
Study 31719604 — intervention group
Group type: EXPERIMENTAL
Intervention: Total adiponectin quartile (Q4)
Number of subjects: 1228
Study 31719604 — intervention group
Group type: COMPARATOR
Intervention: High molecular weight (HMW) adiponectin quartile
Number of subjects: 1228
Study 28963159 — intervention group
Group type: EXPERIMENTAL
Intervention: TiPEEK (polyetheretherketone cage with titanium coating)
Number of subjects: 40
Study 28963159 — intervention group
Group type: COMPARATOR
Intervention: PEEK (polyetheretherketone cage without titanium coating)
Number of subjects: 40
Study 26560511 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (0.75 mg twice daily in blocks 1-3 and 1.5 mg twice daily in blocks 4-6)
Number of subjects: 22
Study 26560511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24162942 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual based coping intervention (8 sessions delivered by supervised psychology graduates)
Number of subjects: 260
Study 24162942 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual based coping intervention
Number of subjects: 260
Study 24162942 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 260
Study 21831581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular multimodal drug injection
Number of subjects: 286
Study 21831581 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 286
Study 20141383 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 80
Study 20141383 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreation therapy
Number of subjects: 80
Study 20141383 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 80
Study 17047021 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 infusion
Number of subjects: 10
Study 17047021 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 16398435 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thermotherapy with rabdosia liquid, starting from 1-2 months after operation, once tri-monthly for one year.
Number of subjects: 123
Study 16398435 — intervention group
Group type: COMPARATOR
Intervention: Intravesical perfusion of mitomycin C, starting from 2 weeks after operation, once weekly for six times, thereafter once monthly for one year.
Number of subjects: 123
Study 16398435 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thermotherapy with rabdosia liquid
Number of subjects: 123
Study 16398435 — intervention group
Group type: COMPARATOR
Intervention: Intravesical perfusion of mitomycin C
Number of subjects: 123
Study 12196768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye-spray (0.1% indigo carmine used to coat the entire colon during withdrawal from the cecum)
Number of subjects: 259
Study 12196768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dye)
Number of subjects: 259
Study 9665616 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant (left) hand task in right handers
Number of subjects: 0
Study 9665616 — intervention group
Group type: COMPARATOR
Intervention: Dominant (right) hand task in right handers
Number of subjects: 0
Study 9665616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hand tasks in left handers
Number of subjects: 0
Study 8591624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 26
Study 8591624 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 26
Study 2760254 — intervention group
Group type: COMPARATOR
Intervention: Dilevalol (single dose)
Number of subjects: 20
Study 2760254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (chronic treatment)
Number of subjects: 20
Study 65039 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus bleomycin
Number of subjects: 34
Study 65039 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide plus vincristine
Number of subjects: 34
Study 31719301 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometry-based models (ASMM 1-ASMM 4) developed using height, weight, triceps skinfold thickness (TSFT), age, and menopausal status (MS) as independent variables.
Number of subjects: 332
Study 29188863 — intervention group
Group type: EXPERIMENTAL
Intervention: Total baseline plasma homocysteine
Number of subjects: 177
Study 29188863 — intervention group
Group type: EXPERIMENTAL
Intervention: Total baseline plasma homocysteine in subjects with low baseline omega-3 index (< 4.72%)
Number of subjects: 177
Study 29188863 — intervention group
Group type: EXPERIMENTAL
Intervention: Total baseline plasma homocysteine in subjects with high baseline omega-3 index
Number of subjects: 177
Study 26004026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucogyne® applied 3 times a week for 84 days
Number of subjects: 47
Study 23715873 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine supplementation (3 × 100 mg/day for 6 weeks)
Number of subjects: 12
Study 23715873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20415525 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous local anesthesia (LA)
Number of subjects: 44
Study 20415525 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regional anesthesia (IVRA)
Number of subjects: 44
Study 20415525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 19672237 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg daily for the 1st month, increasing to 16 mg daily; 6 patients received 24 mg from the 3rd month)
Number of subjects: 25
Study 19672237 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine with antipsychotic therapy (15 patients)
Number of subjects: 25
Study 16540614 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blastocyst-stage embryo (day 5)
Number of subjects: 351
Study 16540614 — intervention group
Group type: COMPARATOR
Intervention: Single cleavage-stage embryo (day 3)
Number of subjects: 351
Study 15258329 — intervention group
Group type: EXPERIMENTAL
Intervention: New test (Cervical acid phosphatase - CAP)
Number of subjects: 1500
Study 15258329 — intervention group
Group type: COMPARATOR
Intervention: Pap control (standard Pap test)
Number of subjects: 1500
Study 10691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet omitting known pseudoallergens for 6 weeks
Number of subjects: 50
Study 10691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet omitting known pseudoallergens
Number of subjects: 50
Study 10691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with food rich in pseudoallergens
Number of subjects: 50
Study 10691900 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind exposure to food additives
Number of subjects: 50
Study 9426670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent liposculpture combined with external ultrasound
Number of subjects: 30
Study 9426670 — intervention group
Group type: COMPARATOR
Intervention: Tumescent liposculpture alone
Number of subjects: 30
Study 8224683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate solution
Number of subjects: 100
Study 8224683 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte lavage
Number of subjects: 100
Study 2869210 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic peptide vaccine (18-aminoacid E. coli heat-stable toxin and 26-aminoacid heat-labile toxin B subunit)
Number of subjects: 13
Study 2869210 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic peptide vaccine
Number of subjects: 13